Tsumura & Co
Tsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines, as well as Kampo po… Read more
Tsumura & Co (TSUA) - Net Assets
Latest net assets as of September 2025: €326.49 Billion EUR
Based on the latest financial reports, Tsumura & Co (TSUA) has net assets worth €326.49 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€516.49 Billion) and total liabilities (€190.00 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €326.49 Billion |
| % of Total Assets | 63.21% |
| Annual Growth Rate | 9.7% |
| 5-Year Change | 41.58% |
| 10-Year Change | N/A |
| Growth Volatility | 6.3 |
Tsumura & Co - Net Assets Trend (2017–2025)
This chart illustrates how Tsumura & Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tsumura & Co (2017–2025)
The table below shows the annual net assets of Tsumura & Co from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €330.11 Billion | +11.76% |
| 2024-03-31 | €295.36 Billion | +8.49% |
| 2023-03-31 | €272.25 Billion | +5.48% |
| 2022-03-31 | €258.11 Billion | +10.70% |
| 2021-03-31 | €233.17 Billion | +9.44% |
| 2020-03-31 | €213.05 Billion | +3.35% |
| 2019-03-31 | €206.14 Billion | +4.89% |
| 2018-03-31 | €196.53 Billion | +24.86% |
| 2017-03-31 | €157.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tsumura & Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 76.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €229.20 Billion | 76.27% |
| Other Components | €71.33 Billion | 23.73% |
| Total Equity | €300.53 Billion | 100.00% |
Tsumura & Co Competitors by Market Cap
The table below lists competitors of Tsumura & Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PNB Housing Finance Limited
NSE:PNBHOUSING
|
$1.58 Billion |
|
Thermon Group Holdings Inc
NYSE:THR
|
$1.58 Billion |
|
GUARANTY TR.HLDG.GDR REGS
F:9JO
|
$1.58 Billion |
|
Mercari Inc
PINK:MRCIF
|
$1.58 Billion |
|
SARTORIUS (UNSP.ADS)/1/5
F:SRT0
|
$1.58 Billion |
|
Taisei Corporation
PINK:TISCY
|
$1.58 Billion |
|
CSG Holding Co Ltd
SHE:000012
|
$1.58 Billion |
|
Highwealth Construction Corp
TW:2542
|
$1.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tsumura & Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 270,801,000,000 to 300,528,000,000, a change of 29,727,000,000 (11.0%).
- Net income of 32,428,000,000 contributed positively to equity growth.
- Dividend payments of 9,021,000,000 reduced retained earnings.
- Share repurchases of 912,000,000 reduced equity.
- Other factors increased equity by 7,232,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €32.43 Billion | +10.79% |
| Dividends Paid | €9.02 Billion | -3.0% |
| Share Repurchases | €912.00 Million | -0.3% |
| Other Changes | €7.23 Billion | +2.41% |
| Total Change | €- | 10.98% |
Book Value vs Market Value Analysis
This analysis compares Tsumura & Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €2250.31 | €23.60 | x |
| 2018-03-31 | €2532.07 | €23.60 | x |
| 2019-03-31 | €2639.54 | €23.60 | x |
| 2020-03-31 | €2684.35 | €23.60 | x |
| 2021-03-31 | €2846.55 | €23.60 | x |
| 2022-03-31 | €3133.93 | €23.60 | x |
| 2023-03-31 | €3299.39 | €23.60 | x |
| 2024-03-31 | €3566.53 | €23.60 | x |
| 2025-03-31 | €3968.02 | €23.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tsumura & Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.79%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.91%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.55x
- Recent ROE (10.79%) is above the historical average (7.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 8.07% | 10.86% | 0.52x | 1.43x | €-2.99 Billion |
| 2018 | 7.49% | 12.30% | 0.40x | 1.52x | €-4.86 Billion |
| 2019 | 7.23% | 12.07% | 0.42x | 1.42x | €-5.59 Billion |
| 2020 | 6.70% | 11.17% | 0.40x | 1.51x | €-6.77 Billion |
| 2021 | 7.04% | 13.17% | 0.36x | 1.47x | €-6.45 Billion |
| 2022 | 7.86% | 14.54% | 0.37x | 1.46x | €-5.14 Billion |
| 2023 | 6.54% | 11.77% | 0.35x | 1.57x | €-8.72 Billion |
| 2024 | 6.17% | 11.08% | 0.35x | 1.58x | €-10.37 Billion |
| 2025 | 10.79% | 17.91% | 0.39x | 1.55x | €2.38 Billion |
Industry Comparison
This section compares Tsumura & Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
No peer company data available for comparison.